PharmAthene gets $5.8 million for SparVax contract

Biodefense company PharmAthene Inc. received a one-time payment of $5.8 million Thursday from the Biomedical Advanced Research and Development Authority (BARDA).

The payment was made to reconcile the actual and provisional rates on the performance of the company’s anthrax vaccine SparVax for actual costs from 2008-2013. The contract with BARDA ended in February.